Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II venetoclax monotherapy in relapsed/refractory BCL-2 positive nodal peripheral T-cell lymphomas
2017-004630-29Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL) and follicular T-cell lymphoma (FTCL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Overall response rate. Started Jun 2021; status: completed.
02
Drugs
venetoclax
03
Conditions
peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)follicular T-cell lymphoma (FTCL)
Beyond the preview
Go deeper on 2017-004630-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004630-29.